Finally, we found that combining cisplatin with a METTL3 inhibitor markedly sensitizes KRAS mutant NSCLC cells to cisplatin exposure, offering a promising strategy for the treatment of NSCLC. This evidence concerns the gene METTL3 and non-small cell lung carcinoma.